ARGX cites strong revenue growth and pipeline progress
ARGX says its Vision 2030 targets are advancing, with strong revenue growth and pipeline expansion via new indications and acquisitions. The company highlights VYVGART in MG and CIDP and adds empasiprubart and FB102 to diversify its immunology portfolio.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.